ReviewArticle QpenAccess

Immunotherapy in HIV Infection


Bhawna Poonia*


Division of Basic Science and Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore 21201, USA

Abstract

Substantial progress has been made in devising successful therapies against Human Immunodefciency Virus (HIV) replication, and antiretroviral therapy (ART) can provide a sustained control of HIV replication. It is, however, associated with at best partial immune reconstitution, as well as lack of elimination of viral reservoirs. Both innate and adaptive immune cell compartments that suffer as a result of HIV replication, fail to recover completely under ART, hence, the need for lifelong therapy once infected. Novel therapeutic approaches are being tested at an encouraging rate and have the potential to improve the odds against the virus. Among them, immunotherapeutic approaches are







References

- Valentin A, Rosati M, Patenaude DJ, Hatzakis A, Kostrikis LG, et al. (2002) Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci U S A 99: 7015-7020.
- Goodier MR, Imami N, Moyle G, Gazzard B, Gotch F (2003) Loss of the CD56hiCD16- NK cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: partial recovery by human growth hormone. Clin Exp Immunol 134: 470-476.
- Mavilio D, Benjamin J, Daucher M, Lombardo G, Kottilil S, et al. (2003) Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A 100: 15011-15016.
- Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, et al. (2007) Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/

human immunodef ciency virus type 1 replication by cell-released antiviral factors including CC chemokines. J Infect Dis 180: 858-861.

11. Leone A, Picker LJ, Sodora DL (2009) IL-2, IL-7 and IL-15 as immuno-